ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Oral Abstract Session

Halfway Through the Marathon: Clinical Candidates in Development

October 25, 2020 | 05:00 PM - 07:00 PM

Location: Simulive

Session Description

Oral Abstract Session

Learning Pathway(s)

  • Glomerular Diseases


  • Samir V. Parikh, MD, FASN
  • Sanja Sever, PhD


  • Two-Year Results from a Randomized, Controlled Study of Obinutuzumab for Proliferative Lupus Nephritis
    05:00 PM - 07:00 PM
    Brad H. Rovin, MD, FASN
  • Complement C5a Receptor Inhibitor Avacopan Improves Renal Function in ANCA Vasculitis
    05:00 PM - 07:00 PM
    David R.W. Jayne, MD, MBChB 
  • Prognostic Value of Persistent Proteinuria and Hematuria After Induction Therapy in ANCA-Associated Vasculitides
    05:00 PM - 07:00 PM
    Nicolas Benichou 
  • Belimumab (BEL) Improves Renal Outcomes in Active Lupus Nephritis (LN): A Phase 3 Randomized, Placebo (PBO)-Controlled Trial
    05:00 PM - 07:00 PM
    Brad H. Rovin, MD, FASN
  • 24-Week Interim Analysis of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Atacicept in Patients with IgA Nephropathy and Persistent Proteinuria
    05:00 PM - 07:00 PM
    Jonathan Barratt, MBChB, PhD 
  • Grading System Utilizing Total Score of Oxford Classification for Predicting Renal Prognosis in IgA Nephropathy
    05:00 PM - 07:00 PM
    Yoei Miyabe, MD, PhD 
  • Development of a Deep Learning Model to Predict ESKD in Patients with Immunoglobulin A Nephropathy (IgAN) at Kidney Biopsy Time
    05:00 PM - 07:00 PM
    Francesco Paolo Schena, MD, FASN
  • Complete Remission of Proteinuria in Patients with Focal Segmental Glomerulosclerosis Treated with Sparsentan, a Dual Endothelin and Angiotensin Receptor Antagonist, in the DUET Trial
    05:00 PM - 07:00 PM
    Jonathan Hogan, MD
  • LNP023: A Novel Oral Complement Alternative Pathway Factor B Inhibitor Safely and Effectively Reduces Proteinuria in C3 Glomerulopathy
    05:00 PM - 07:00 PM
    Edwin Kwan Soon Wong, MBChB, PhD
  • Characteristics and Outcomes of Pregnancy-Triggered Atypical Hemolytic-Uremic Syndrome (aHUS): Global aHUS Registry Analysis
    05:00 PM - 07:00 PM
    Fadi Fakhouri, MD, PhD